ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

How Ibrutinib Has Transformed the Treatment Paradigm of CLL

Javier Pinilla-Ibarz, MD, PhD
Published Online:3:23 PM, Thu September 21, 2017

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses how ibrutinib (Imbruvica) has transformed the treatment landscape of chronic lymphocytic leukemia (CLL).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.